| Abstract | Darunavir (TMC114) is a nonpeptidic peptidomimetic HIV protease inhibitor (PI), with a high binding affinity and a close fit within the substrate envelope. Darunavir shows potent in vitro activity against a broad range of clinical isolates of HIV type 1 (HIV-1), including those with decreased susceptibility to most available PIs. The bioavailability of oral darunavir is increased when it is coadministered in combination with low-dose (100mg) ritonavir. In the POWER 1 and POWER 2 trials, two 144-week randomised phase IIb trails, a reduction in plasma HIV-1 RNA levels of > or = 1 log10 copies/mL (primary endpoint) occurred in 77% and 62% of treatment-experienced recipients of darunavir plus ritonavir (darunavir/ritonavir) 600mg/100mg twice daily (in combination with an optimised background regimen) [vs 25% and 14% of control PI (CPI) recipients; p < 0.001] at week 24. Results are from primary analyses (n = 301 and 201). In a pooled subgroup analysis of data from the POWER 1 and 2 trials, reductions in HIV-1 RNA levels of > or = 1 log10 copies/mL were achieved in 61% of patients treated with darunavir/ritonavir 600mg/100mg twice daily verus 15% of CPI recipients (p < 0.0001) at week 48. Darunavir/ritonavir 600mg/100mg was generally well tolerated in the POWER 1 and 2 trials, with a tolerability profile similar to that of comparator CPIs. |
| Authors | Caroline Fenton, Caroline M Perry
(Affiliation: Wolters Kluwer Health | Adis, Auckland, New Zealand.)
|
| Journal | Drugs
(Drugs)
Vol. 67
Issue 18
Pg. 2791-801
( 2007)
ISSN: 0012-6667 New Zealand |
| PMID | 18062724
(Publication Type: Journal Article, Review)
|
| Chemical References |
- HIV Protease Inhibitors
- Sulfonamides
- darunavir
|
| Topics |
- Clinical Trials as Topic
- HIV Infections
(drug therapy)
- HIV Protease Inhibitors
(adverse effects, therapeutic use)
- HIV-1
(drug effects)
- Humans
- Sulfonamides
(adverse effects, therapeutic use)
- Treatment Outcome
|
